Pharmaceutical giant Eli Lilly (NYSE:LLY) aims to bring its experimental oral weight-loss drug orforglipron to India as it sees scope for such products in the world’s most populous nation, a senior executive told Reuters on Thursday.
“I do think there is promise for products like that (orforglipron) in India, if it does get approved,” Winselow Tucker, Lilly India’s president, said at an event in Mumbai.
Tucker, however, did not indicate when Lilly plans to launch the drug.
The drugmaker has bid for approval for the experimental pill after the latest clinical data showed it lowered average blood sugar and weight in a head-to-head trial of adults with type 2 diabetes more effectively than rival Novo Nordisk’s (NVO) older GLP-1 pill Rybelsus.
